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Context 
Dementia is a chronic disease with insidious onset. Thus, Alzheimer disease can be 
present years, or even decades, before the clinical onset of Alzheimer dementia.1,2 Much 
research attention is being paid to biomarkers which, singly or in combination, may help 
identify which patients will go on to develop Alzheimer dementia while they are still 
asymptomatic, but their predictive validity is still inadequate.3 Many patients seen in 
clinical practice fall into the grey area of having some, relatively minor, memory 
problems which have little impact on their day-to-day functioning. These criteria are at 
the core of all definitions of mild cognitive impairment (MCI) and similar categories, the 
prognosis of which are difficult to forecast. The cognitive component can be more 
accurately characterised with a longitudinal assessment. However, the question of 
whether or not a patient’s functional ability is ‘normal’ is, in fact, a value judgement 
related to expectation. Values are integral to all medical diagnoses, although they are 
not always explicitly apparent.4 With clear benefits ensuing from appropriate early 
diagnosis, the question of how early a person can be diagnosed with dementia is not 
mere academic speculation. It has clear clinical relevance regarding the starting of 
memory treatment and it is vital to acknowledge the value judgement at the centre of this 
question. There is evidence from several systematic reviews that cholinesterase 
inhibitors are not efficacious in MCI and are associated with substantial side effects.5-7 
 
Methods 
This review included experimental, quasi-experimental or observational studies of 
memory treatment (cholinesterase inhibitors or memantine) in people with MCI. The 
outcomes reported were: change in cognition (measured by the Mini-Mental State 
Examination and the Alzheimer disease assessment scale cognitive subscale), function 
(measured by the Alzheimer Disease Cooperative Study Inventory-Activities of Daily 
Living), behaviour (measured by the NPI), mortality and side effects. The protocol was 
registered in advance of the study and the authors followed Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses guidelines in their reporting of the review. 
Results are reported as relative risks (RR) and CI. 
 
Findings 
Eight RCTs (reported in 10 papers) including 4711 people with MCI were included in the 
review. Only one study investigated the use of memantine for MCI and this was only 
included in the serious adverse events analysis. There were no differences seen in 
terms of cognition, function or behaviour between individuals receiving cholinesterase 
inhibitors or placebo. Similarly, there was no difference in mortality—overall or 
treatment-related—or serious adverse events between the cognitive enhancer and 
placebo groups. However, substantially higher nausea (RR=3.04, 95% CI 2.52 to 3.66), 
diarrhoea (RR=2.33, 95% CI 1.74 to 3.13), vomiting (RR=4.40, 95% CI 3.21 to 6.03) and 
 2 
headaches (RR=1.27, 95% CI 1.04 to 1.53) were reported in the treatment groups 
compared with placebo. Similar results were seen in the single study reporting 
treatment-related harms. A single study of galantamine reported more bradycardia 
(RR=1.52, 1.04 to 2.22), but fewer falls (RR=0.71, 95% CI 0.52 to 0.98) compared with 
placebo. 
 
Commentary 
This systematic review and meta-analysis is the first to differentiate between overall 
harms and treatment-related harms. Nevertheless, its findings echo those of a series of 
earlier systematic reviews.5-7 This is the first review to include memantine but only one 
study examined this drug and it could only be included in a subset of analyses. 
Presumably because of the limited number of studies, the authors combined outcomes 
from a wide variety of study durations and performed meta-regression to investigate 
different effects over time. 
 
It is concerning that the authors report these medications can be obtained by special 
authorisation in Canada, as the evidence is clear — cholinesterase inhibitors and 
memantine should not be prescribed in MCI. However, the core problem is a 
philosophical one: MCI is a description, not a diagnosis and further research attention is 
urgently required to better characterise people with minor cognitive impairment and 
minimal functional impairment in order to be able to predict who will go on to develop 
clinical dementia and who will not. 
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